# Supplementary material. Autoimmune hepatitis data abstraction form

**Autoimmune hepatitis**

**Surveillance Officer ID:**

**Hospital/admission ID:**

**AESI record ID*:* \_\_\_ \_\_\_ *\_\_\_*\_\_\_ \_\_\_ *\_\_\_***

**Date of record:** **\_\_\_/ \_\_\_/ \_\_\_\_\_\_** (DD/MM/YYYY)

*Please fill/check the following information obtained from chart review:*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Line** |  | **Yes** | **No** | **Test not done OR insufficient information** |
| **1** | **Presence of an alternative diagnosis:**  If YES, check all that apply:   * Viral hepatitis including Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis Epstein Barr and cytomegalovirusa * Drug induced liver injury * Alcohol-associated hepatitis * Metabolic liver disease including Wilson’s disease, Alpha-1-antitrypsin deficiency, hereditary hemochromatosis, iron overload * Other autoimmune liver diseases: primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), Celiac syndrome) * Other   Specify: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |  |  |  |
| **Line** |  | **Yes** | **No** | **Test not done OR insufficient information** |
| **2** | **Liver histology** | | | |
| 3 | Characteristic histology (interface hepatitis (death of hepatocytes at the interface of the hepatic parenchyma and the portal zone connective tissue, accompanied by a variable degree of inflammation and fibrosis) and lymphocytes and plasma cell infiltration of the liver. Perivenulitis (Inflammatory lesions involving the perivenular regions of the liver parenchyma) of the central vein may be a prominent lesion in acute severe AIH cases) |  |  |  |
| 4 | Atypical histology (interface hepatitis and lymphocytes infiltration in the absence of plasma cells) |  |  |  |
| **5** | **Serum biochemical tests** | | | |
| 6 | Alanine aminotransferase (ALT) above the upper limit of normal (ULN) |  |  |  |
| 7 | Aspartate aminotransferase (AST) above the ULN |  |  |  |
| 8 | Immunoglobulin G (IgG) above the ULN |  |  |  |
| 9 | Immunoglobulin G (IgG) within normal limits |  |  |  |
| **10** | **Serological tests confirming presence of autoantibodiesb** | | | |
| 11 | ANA (antinuclear antibodies) |  |  |  |
| 12 | Anti-SMA (smooth muscle antibodies) |  |  |  |
| 13 | Anti-LKM1 (antibodies to liver-kidney microsome type 1) |  |  |  |
| 14 | Anti-SLA (antibodies to soluble liver antigen) |  |  |  |
| **15** | **Assessment to exclude alternative diagnosis for illness** | | | |
| 16 | By a medical specialist (e.g. hepatologist, gastroenterologist) |  |  |  |
| 17 | By a medical professional |  |  |  |

aPossible tests to determine viral hepatisis (Hepatitis A (IgM anti-HAV), Hepatitis B (HBsAg, total anti-HBc, anti-HBs), Hepatitis C (anti-HCV ab, HCV RNA PCR), Hepatitis E (IgM/IgG anti-HEV RNA PCR))

b Approximate percentages of autoantibodies in AIH cases: ANA (antinuclear antibodies) in approx. 60-70% of AIH, Anti-SMA (smooth muscle antibodies) in up to 85% of AIH and Anti-LKM1 (antibodies to liver-kidney microsome type 1) in approx. 70% of AIH-2. Rarely other antibodies are seen including Anti-LC-1 (anti-liver cytosol -1 antibody) in 30% AIH-2, anti-SLA/LP (anti-soluble liver antigen/liver pancreas antibodies) in 20–30% AIH-1 and AIH-2, anti-LKM3 (anti-liver-kidney microsomal antibody type 3) in 20–30% of pediatric and up to 10% of adult AIH cases.

**Brighton Collaboration levels of diagnostic certainty**

**Autoimmune Hepatitis**

|  |  |  |
| --- | --- | --- |
| **Level 1 of diagnostic certainty**  [ ] 6 boxes checked | **Level 2 of diagnostic certainty**  [ ] 6 boxes checked | **Level 3 of diagnostic certainty**  [ ] 6 boxes checked |
| Characteristic liver histology (YES to Line 3)  **AND** | Characteristic liver histology (YES to Line 3)  **AND** | Characteristic or atypical liver histology (YES to Line 3 or 4)  **AND** |
| Elevated serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above the upper limit of normal (ULN) (YES to Lines 6 or 7)  **AND** | Elevated serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above the ULN (YES to Lines 6 or 7)  **AND** | Elevated serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above the ULN (YES to Lines 6 or 7)  **AND** |
| Immunoglobulin G (IgG) above the ULN (YES to Line 8)  **AND** | IgG within normal limits (YES to Line 9)  **AND** | IgG within normal limits or above the ULN (YES to Line 8 or 9)  **AND** |
| One or more autoimmune antibodies present (YES to one or more of Lines 11-14)  **AND** | One or more autoimmune antibodies present (YES to one or more of Lines 11-14)  **AND** | Negative results or autoimmune antibodies test not done (No or test not done for Lines 11-13)  **AND** |
| Assessment by a medical specialist (YES to Line 16)  **AND** | Assessment by a medical specialist (YES to Line 16)  **AND** | Assessment by a medical professional (YES to Line 17)  **AND** |
| No alterative diagnosis for symptoms  (NO to Line 1) | No alterative diagnosis for symptoms  (NO to Line 1) | No alterative diagnosis for symptoms  (NO to Line 1) |

**After review of findings, please check Level of diagnostic certainty:**

[ ] Level 1 for autoimmune hepatitis

[ ] Level 2 for autoimmune hepatitiss

[ ] Level 3 for autoimmune hepatitis

[ ] Level 4: Reported autoimmune hepatitis case with insufficient evidence to meet case definition

[ ] Level 5: Not a case of autoimmune hepatitis